OctoPlus N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
31 mrt 2011 - 09:02
Statutaire naam
OctoPlus N.V.
Titel
OctoPlus' licensee Biolex presents final Phase IIb results at EASL highlighting tolerability advantages of Locteron in treatment of HCV
Bericht
Presentation highlights strong antiviral activity and SVR rates, significant reductions in flu-like adverse events and reduced rates of depression
Significant tolerability advantages and a 50% reduction in dosing frequency support Locteron’s attractiveness for use in new triple- and quad-combination regimens
Leiden, the Netherlands, 31 March 2011 - OctoPlus N.V. (“OctoPlus” or the “Company”) (Euronext: OCTO) announces that its licensee Biolex Therapeutics will present today final results from the Locteron® Phase IIb clinical study at the 46th Annual Meeting of the European Association for the Study of the Liver (EASL) in Berlin, Germany. These data highlight important tolerability advantages of Locteron versus current HCV treatments.
Jan Egberts, CEO of OctoPlus, comments: “These positive final results from the Phase IIb clinical study with Locteron further confirm the long term benefits of Locteron’s controlled release mechanism. Our PolyActive technology has enabled the development of an interferon alpha with a significantly improved side effect profile, achieving both a 50% reduction in flu-like adverse events and substantially lower rates of depression compared to conventional interferon treatments. In combination with its reduced injection frequency, these benefits clearly position Locteron as the interferon of choice for future hepatitis C treatments.”
Datum laatste update: 08 oktober 2024